Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCR&#x3b1;&#x3b2;/CD19 depletion or post-transplant cyclophosphamide

Leukemia

Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma

Br J Haematol

Yoshimitsu M, Tanaka T, Nakano N, Kato K, Muranushi H, Tokunaga M, Ito A, Ishikawa J, Eto T, Morishima S, Kawakita T, Itonaga H, Uchida N, Tanaka M, Akizuki K, Ishitsuka K, Ohigashi H, Ota S, Ando T, Kanda Y, Fukuda T, Atsuta Y, Fuji S, ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy

doi: 10.1111/bjh.19835

Further Publications

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation

Br J Haematol

Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Remberger M, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV

doi: 10.1111/bjh.70006

Further Publications

Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial

Lancet Haematol

Yu S, Huang F, Xu N, Zhang Z, Liu C, Xu X, Fan Z, Zeng X, Liu Q, Qiu G, Xi X, Lin R, Liang X, Jiang Y, Dai M, Jin H, Li X, Wang S, Wu M, Sun J, Xuan L, Liu Q

doi: 10.1016/S2352-3026(24)00372-7

Further Publications

Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation

Am J Hematol

Yoshimura K, Nakasone H, Tamaki M, Hosoi H, Kameda K, Uchida N, Doki N, Fukuda T, Yoshihara S, Mori Y, Nakamae H, Tanaka M, Katayama Y, Eto T, Hasegawa Y, Ota S, Takahashi S, Yoshimitsu M, Ishimaru F, Kanda J, Atsuta Y, Yakushijin K

doi: 10.1002/ajh.27709

Further Publications

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703

J Clin Oncol

Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ

doi: 10.1200/JCO.24.00921

Leukemia

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

Br J Haematol

Konuma T, Shimomura Y, Mizuno S, Yamasaki S, Yui S, Uchida N, Doki N, Tanaka M, Yoshihara S, Eto T, Katayama Y, Katsuoka Y, Tokunaga M, Ota S, Sakata-Yanagimoto M, Ishiwata K, Kanda Y, Kawakita T, Onizuka M, Kanda J, Fukuda T, Atsuta Y, Yanada M

doi: 10.1111/bjh.20208

Further Publications

Defining a CMV viral load threshold for pre-emptive therapy in paediatric haematopoietic stem cell transplant recipients

Br J Haematol

Duret A, Charles O, Margetts BK, Booth J, Brown JR, Best T, Fernandes S, Amrolia P, Chiesa R, Silva J, Worth A, Standing JF, Rao K, Whittaker E, Gil E, Breuer J

doi: 10.1111/bjh.20254

Leukemia

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation

Br J Haematol

Perutelli F, Boccellato E, Montalbano MC, Catania G, Deodato M, Frustaci AM, Innocenti I, Moia R, Quaglia FM, Quaresmini G, Rivela P, Gaidano G, Krampera M, Laurenti L, Rambaldi A, Bruno B, Vitale C, Coscia M

doi: 10.1111/bjh.19976

Further Publications

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies

Lancet Oncol

Khatsuria F, McMullan C, Aiyegbusi OL, Shaw KL, Iqbal R, Kinsella F, Wilson K, Pyatt L, Lewis M, Wheldon SMR, Burns D, Chakraverty R, Calvert M, Hughes SE

doi: 10.1016/S1470-2045(24)00256-0

Oncology · Hematology

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post-transplant cyclophosphamide

Related content

Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation

Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial

Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

Defining a CMV viral load threshold for pre-emptive therapy in paediatric haematopoietic stem cell transplant recipients

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation

Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies